The Latest Breaking News from Lilly

Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside

Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low?

MarketBeat · Feb 17, 2025

Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial

Eli Lilly is still seeing rapid sales growth for its diabetes and weight loss drugs. However, one drug waiting in the wings hopes to be its next blockbuster.

MarketBeat · Feb 13, 2025

Meet the 24-year-old helping Lilly test a preventive Alzheimer’s drug

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same age their parents did.

Fortune · Feb 6, 2025

What Does the Future Hold for Eli Lilly?

Eli Lilly's two major GLP-1 drugs have dominated headlines, but a slate of new treatments in development—and some already available—suggest a bright future.

MarketBeat · Jan 28, 2025

The Misty Isle’s magic: Feasting my way around the Isle of Skye

TOP TABLES: What happens when a food writer swaps London’s bustle for Scotland’s beauty? Lilly Subbotin discovers the unexpected culinary delights of Skye – from langoustines on a harbour boat to black garlic butter that tastes like witchcraft

The Independent UK · Jan 23, 2025

How we diagnose and define obesity is set to change – here’s why, and what it means for treatment

Obesity is linked to many common diseases, such as type 2 diabetes, heart disease, fatty liver disease and knee osteoarthritis.

The Conversation · Jan 14, 2025

Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity

Eli Lilly shares are down 17.7% from its highs. The company posted 128% YoY revenue jump in its Mounjaro GLP-1/GIP treatment with no signs of slowing down.

MarketBeat · Jan 14, 2025

Eli Lilly's Q4 2024 Earnings: What to Expect

Eli Lilly is scheduled to release its Q4 earnings report next month, and analysts forecast triple-digit profit growth.

Barchart · Jan 13, 2025

Elon Musk Weighs In on Weight-Loss Drug Stocks. Is LLY or NVO a Better Buy?

Elon Musk’s preference for Eli Lilly’s Mounjaro over Novo Nordisk’s Ozempic has sparked increased interest in weight-loss drug stocks.

Barchart · Jan 2, 2025

Is Eli Lilly Stock a Buy, Sell, or Hold for 2025?

Eli Lilly is very close to joining the $1 trillion club. Should you buy shares now?

Barchart · Dec 30, 2024